A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

by palligoelme@gmail.com | Sep 16, 2025 | Clinical Trials

​ Conditions: Non-Small Cell Lung Cancer Interventions: Drug: IN10018 in combination with D-1553; Drug: anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed Sponsors: InxMed (Shanghai) Co., Ltd. Not yet recruiting Conditions: Non-Small Cell Lung...

Progesterone and Muscle Protein Synthesis in Premenopausal Women (MP4-MPS)

by palligoelme@gmail.com | Sep 15, 2025 | Clinical Trials

​ Conditions: Healthy Volunteers; Female; Progesterone; Premenopausal Interventions: Drug: Micronized progesterone (oral capsules); Drug: placebo capsule Sponsors: McMaster University Not yet recruiting Conditions: Healthy Volunteers; Female; Progesterone;...

A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression

by palligoelme@gmail.com | Sep 15, 2025 | Clinical Trials

​ Conditions: Glioblastoma Interventions: Other: samples Sponsors: University Hospital, Bordeaux; University of Bordeaux Not yet recruiting Conditions: Glioblastoma Interventions: Other: samples Sponsors: University Hospital, Bordeaux; University of Bordeaux Not yet...

The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis

by palligoelme@gmail.com | Sep 15, 2025 | Clinical Trials

​ Conditions: Cirrhosis; Decompensation; Transjugular Intrahepatic Portosystemic Shunt (TIPS); Survival Analysis Sponsors: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Zhongnan Hospital; Yichang Central People’s...

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

by palligoelme@gmail.com | Sep 15, 2025 | Clinical Trials

​ Conditions: Recurrent Cervical Cancer Interventions: Drug: RC48; Drug: QL1706 Sponsors: Qilu Hospital of Shandong University Not yet recruiting Conditions: Recurrent Cervical Cancer Interventions: Drug: RC48; Drug: QL1706 Sponsors: Qilu Hospital of Shandong...